Akeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer
Portfolio Pulse from
Akeso, Inc. has enrolled the first patient in a Phase III clinical trial for ivonescimab, a PD-1/VEGF bispecific antibody, combined with chemotherapy for treating triple-negative breast cancer.
February 21, 2025 | 1:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akeso has initiated a Phase III trial for its drug ivonescimab, targeting triple-negative breast cancer, marking a significant step in its drug development pipeline.
The initiation of a Phase III trial is a critical step in drug development, indicating progress and potential future revenue if successful. This news is likely to positively impact Akeso's stock price in the short term as it demonstrates advancement in their pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90